UPMC Team Performs First U.S. LIVE Procedure to Stop Heart Failure Progression

University of Pittsburgh Medical Center's picture
Printer-friendly versionPrinter-friendly version

PITTSBURGH, Oct. 3, 2017 – A multidisciplinary team of UPMC physicians recently completed the first Less Invasive Ventricular Enhancement™ (LIVE™) procedure in the United States to treat patients whose hearts can no longer pump enough blood to the rest of their body due to coronary artery disease.
 
Ischemic cardiomyopathy, as this condition is known, is one of the leading causes of cardiac death. The condition results when damaged muscle from previous heart attacks prevents the heart from pumping the necessary amount of blood to the body. The scar tissue that develops following the heart attack can lead to an abnormal shape and size of the left ventricle and impaired overall heart function.
 
Scar tissue combined with the enlarged size of the left ventricle puts additional stress on the rest of the heart, leading to a gradual heart failure progression,” said Catalin Toma, M.D., director of interventional cardiology at UPMC. “Reducing this stress can stop heart failure from advancing, and this procedure provides a less invasive option for slowing the progression to end-stage heart failure.”
 
Toma worked side by side with Christopher Sciortino, M.D., Ph.D., surgical director of UPMC’s Advanced Heart Failure Center, along with anesthesiologists and advanced imaging specialists, to use the Revivent TC™ system from BioVentrix Inc. to bring the left ventricle back to its normal shape and size.
 
The Revivent TC system uses a minimally invasive approach to attach small anchor pairs to the inside and outside of the heart. The anchors pull towards each other, synching any scar tissue away from the heart’s remaining functional tissue, bringing the left ventricle closer to its regular formation.
 
The LIVE procedure was approved in Europe in 2016, and UPMC’s surgery was the first in the U.S. under a protocol that allows the Revivent TC system to be used as an investigational device in a multicenter clinical study to collect safety and effectiveness data. To date, 130 LIVE procedures have been performed worldwide.
 
“At UPMC, we see a high volume of patients with advanced heart failure, and we have extensive teams dedicated to their treatment and surgical needs,” said Sciortino. “We are hopeful that the LIVE procedure will provide a new, less invasive option for preventing heart failure and improving the quality
of life for our patients.”
 
More information on the LIVE procedure is available on the BioVentrix website, and information about heart failure is available on the UPMC Heart and Vascular Institute website.
Copy this html code to your website/blog to embed this press release.

Comments

Post new comment

19 + 0 =

To prevent automated spam submissions leave this field empty.